Eva is studying Medicinal Chemistry with Professional Studies BSc (Hons) at the University of Salford. Eva is working on the synthesis and SAR of substituted benzothiazoles for the treatment of neurodegenerative diseases including MS and SMA.
Priscilla is a student at the University of Huddersfield studying for a MSci in Pharmaceutical Chemistry. Priscilla is spending her placement year here at the LDDN and is focused on the asymmetric synthesis of a number of different heterocycles that increase survival motor neuron protein for the treatment of Spinal Muscular Atrophy.
Kristy is a student at the University of Bath, UK, studying for a BSc (Hons) in Natural Sciences (Major in Pharmacology, Minor in Organic Chemistry). Kristy is making new anlogs of lead HIF2a inhibitor as a potential treatment for renal cancer.
Dawid originally joined the group in January 2017, as a coop student from Northeastern University.
Dawid is working on the synthesis of analogs in our SMA series that increases transcription of the survival motor neuron protein for the treatment of Spinal Muscular Atrophy. Dawid is also developing water soluble pro-drugs of a poorly soluble drug that we are re-purposing for AD. Dawid plans to go to medical school following graduation.
Lin Lin originally joined the group in January 2015, as a coop student from Northeastern University. Lin developed the SAR on the SOD1 and CMT projects. After graduating from Northeastern, Lin is now back at the LDDN as a researcher and plans to go to medical school following graduation.
Dr. Hrvoje (Harry) Lusic joined the LDDN as a postdoctoral research fellow in medicinal chemistry in 2013.
His current research efforts are aimed at finding and optimizing potential treatments for SMA, ALS and Alzheimer's disease. Hrvoje obtained a B.S. in Chemistry in 2002, and an M.S. in Polymer Chemistry in 2004, both at Wright State University in Dayton, Ohio. Hrvoje continued his graduate studies at the lab of Alexander Deiters at North Caroline State University, where he worked on synthesis and evaluation of unnatural nucleosides and small-molecule probes as a means of control of biological processes. After earning his Ph.D. in the summer of 2009, he began a postdoctoral appointment at Boston University under the direction of Mark Grinstaff. His studies there were focused on the synthesis and characterization of computed tomography contrast agents.
Alyssa originally joined the LDDN in January 2014 as a Northeastern coop student and after graduation from Northeastern in 2015 she rejoined the LDDN as a researcher. Over the years Alyssa made many important contributions to the SMA project including her work on the thiazolopyridine series and co-authoring two review articles on treatments for SMA. Alyssa will be starting medical school in the fall 2017.
Anna is a student at the University of Bath studying for an MSci (Hons) in Natural Sciences (Major in Chemistry, Minor in Pharmacology. Anna is spending her third year placement here at the LDDN. She is focused on developing new SAR for the EAAT2 project for the treatment of AD and ALS.
Dr. Kevin Hodgetts
Director of The Laboratory for Drug Discovery in Neurodegeneration
65 Landsdowne Street
Cambridge, Massachusetts 02139
Kevin has a broad background in organic and medicinal chemistry, with experience in both industrial and academic drug discovery. Kevin spent over 15 years of experience working on treatments for diseases of the central nervous system. Compounds from two projects that he was involved in have entered clinical trials. Kevin joined the LDDN in September 2012, to work with the academic community to design new and innovative strategies for drug discovery for neurodegenerative diseases. Kevin is Assistant Professor of Neurology at Brigham and Women's Hospital and Harvard Medical School. He also co-founded Klogene Therapeutics with Professor Carmela Abraham.
Dr. Xiao (Elliot) Wang is a Researcher and Instructor at the LDDN.
Dr. Wang originally joined the LDDN as a postdoctoral Research Fellow in Medicinal Chemistry in 2011, and was promoted to his current position in 2012. His research efforts are aimed at finding and optimizing small molecules as potential treatments for neurodegeneration. Dr. Wang obtained his Ph.D. from University of Pittsburgh in 2009, working with Professor Dennis Curran on organic synthesis. From 2009-2011, he gained postdoctoral experience at Massachusetts Institute of Technology with Professor Stephen Buchwald. Dr Wang is a specialist in multiple synthesis fields such as asymmetric catalysis, organofluorine chemistry, peptide synthesis and manufacturing APIs in continuous flow.